Skip to main
DWTX

DWTX Stock Forecast & Price Target

DWTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Dogwood Therapeutics Inc. has demonstrated significant financial potential following the announcement of a new licensing agreement with Serpin Pharma, granting global rights to SP16 for cancer-related pain indications. The company's growth outlook is further supported by the raised 12-month price target to $12.00 per share, reflecting increased confidence in future revenues from its product candidates, including IMC-1 and IMC-2. With its focus on advancing novel antiviral therapies to address conditions such as fibromyalgia and long COVID, Dogwood Therapeutics positions itself favorably in the biotechnology sector.

Bears say

Dogwood Therapeutics Inc. is a development-stage biotechnology company specializing in novel antiviral therapies for conditions exacerbated by viral infections, such as fibromyalgia and long COVID. The company continues to depend heavily on R&D funding, with significant financial losses reported, raising concerns about its ability to sustain operations and secure investments in the long term. Additionally, the market's skepticism regarding the efficacy and commercialization potential of its primary product candidates, IMC-1 and IMC-2, further contributes to a pessimistic outlook for the company's stock performance.

DWTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dogwood Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dogwood Therapeutics, Inc. (DWTX) Forecast

Analysts have given DWTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, DWTX has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dogwood Therapeutics, Inc. (DWTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.